Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranalexin-1G
- Development stage
- Preclinical
- Lead developer
- University of Campania Luigi Vanvitelli
- Modality
- Peptides
- Administration
- Topical
01
Overview
ranalexin-1G is an amphibian-derived antimicrobial peptide (AMP) isolated from the skin epithelium of the North American pig frog (*Rana grylio*). It is a cationic, 20-amino-acid peptide characterized by a conserved C-terminal heptapeptide loop formed by a Cys14–Cys20 disulfide bridge, structurally related to polymyxins. ranalexin-1G exhibits broad-spectrum antimicrobial activity against Gram-positive bacteria (such as *Staphylococcus epidermidis* and *Staphylococcus aureus*), Gram-negative bacteria (such as *Pseudomonas aeruginosa* and *Escherichia coli*), and fungi (such as *Candida albicans*). Additionally, it demonstrates potent antiviral activity against Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), including acyclovir-resistant HSV-1, by blocking viral entry and reducing the expression of infection-related genes (UL27, UL52, and UL54). It is being investigated for the treatment of polymicrobial skin infections, particularly viral-bacterial co-infections, and chronic *P. aeruginosa* lung infections in cystic fibrosis.
- Other names
- Ranalexin-1GRanalexin1GRanalexin 1G
Beyond the preview
Go deeper on ranalexin-1G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranalexin-1G.